Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Immatics NV

Shares of Immatics IMTX, +3.85% gained 9.0% in premarket trading on Thursday after the company said its deal with Bristol Myers Squibb Inc. BMY, -0.65% has expanded to include several off-the-shelf TCR-T and/or CAR-T programs. Bristol's stock was up 0.4%.

Bristol Myers Squibb, Immatics expand CAR-T agreement

TUEBINGEN, Germany & HOUSTON & NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Bristol Myers Squibb (NYSE: BMY), today announced that they have expanded their strategic alliance to pursue the development of multiple allogeneic off-the-shelf TCR-T and/or CAR-T programs. Under this collaboration, Bristol Myers Squibb and Immatics will develop tw

Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Deucravacitinib--Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study....

Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study in Systemic Lupus Erythematosus

Bristol Myers (BMY) secures an FDA approval for two Opdivo-based regimens as the first-line treatment of unresectable advanced or metastatic esophageal squamous cell carcinoma.

Bristol Myers' (BMY) Opdivo Combos Get FDA Nod for ESCC

Bristol Myers Squibb is growing rapidly and can serve as a safe haven for investors worried about the current state of the market and economy. The company faces some risks with patent expirations and high debt, but its promising pipeline and increasing free cash flow will help mitigate both of these issues.

Bristol Myers Squibb: A Safe Spot For A Worrisome Investor

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--US FDA Approves Two Opdivo-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma

U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma

PRINCETON, N.J.--(BUSINESS WIRE)---- $bmy #ASCO--Data from Phase 2 PILOT Study of BMS's CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients....

Data from Phase 2 PILOT Study of Bristol Myers Squibb's CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy

Eli Lilly

Pfizer

Protagonist Therapeutics

Pfizer Inc.'s PFE, +0.96% promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030 if it's approved by U.S. regulators next year.

A new generation of ulcerative colitis drugs is in development. Will they be the blockbusters that pharma wants?

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Bernstein's 38th Annual Strategic Decisions Conference in New York, New York on Thursday, June 2, 2022. Giovanni Caforio, M.D., Board Chair and Chief Executive Officer and Samit Hirawat, Executive Vice President, Chief Medical Officer, Global Drug Development, will answer questions about the company at 8:00 a.m. ET. Investors and the general public are invited to lis

Bristol Myers Squibb to Participate in Bernstein's 38th Annual Strategic Decisions Conference

The legendary investor just might regret selling this big-pharma stock.

Why Did Warren Buffett Just Sell 1 of His Best Stocks of 2022?

Apple

Discovery

Alphabet

Michael Burry, investor, hedge fund manager, and physician known for the “The Big Short” book and movie, seems to be.

Here's how ‘The Big Short' Michael Burry is navigating the financial market now

AbbVie

Both Bristol Myers Squibb and AbbVie spark interest for income- and value-oriented investors. You will see why we favor AbbVie as a better fit for our barbell strategy to build an enduring portfolio for an early retirement.

Bristol Myers Squibb Vs. AbbVie: Who Better Fits Our Barbell?

Booking Hlds

CoreCivic

General Dynamics

GEO Group

Twitter

Michael Burry is back on Twitter, although his first tweet upon his return is not very supportive of current market conditions. The post Michael Burry Says 2022 Is a ‘Plane Crash.

Michael Burry Says 2022 Is a ‘Plane Crash.' Here's What the Legendary Investor Is Betting On.

Geopolitics and risk of economic recession in the U.S. is forcing investors to look for defensive stocks, which refer to health care sector. Healthcare stocks are protected during the recession by both the high percentage of the insured population in the U.S. (about 90%) and the high insurance sum ($250-$500 thsd).

Bristol-Myers Squibb: A Safe Haven In Times Of Uncertainty

Merck

Could these health care stocks be safe bets in the stock market today?

3 Health Care Stocks To Watch Right Now

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO22--Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders

Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders

Amazon

Microsoft

EATON VANCE MANAGEMENT recently filed their 13F report for the first quarter of 2022, which ended on 2022-03-31.

EATON VANCE MANAGEMENT Goes on Buying Spree in 1st Quarter

Devon Energy

McKesson

These high-flying stocks could continue soaring.

3 Stocks Up 25% to 65% That Are Still Smart Buys

Bristol Myers (BMY) phase III CheckMate -901 study fails to meet the primary endpoint of overall survival in patients with untreated unresectable or metastatic urothelial cancer.

Bristol Myers (BMY) Phase III CheckMate -901 Study Disappoints

PRINCETON, N.J.--(BUSINESS WIRE)--BMS Provides Update on CheckMate -901 Trial

Bristol Myers Squibb Provides Update on CheckMate -901 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable or Metastatic Urothelial Carcinoma

NEW YORK & SEOUL--(BUSINESS WIRE)--LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York

LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Deucravacitinib--New Two-Year Deucravacitinib Data Reinforce Durable Efficacy and Consistent Safety Profile in Treatment of Moderate to Severe Plaque Psoriasis

New Two-Year Deucravacitinib Data Reinforce Durable Efficacy and Consistent Safety Profile in Treatment of Moderate to Severe Plaque Psoriasis

Activision Blizzard

Chevron

Globe Life Inc

Kraft Heinz

Coca-Cola

Kroger

Occidental Petroleum

America Movil SAB de CV

These Warren Buffett stocks are helping the Oracle of Omaha be a winner even in a down market. All are generating solid returns in 2022.

The Top 10 Stocks Helping Warren Buffett Beat the Market

Johnson & Johnson

Bristol-Myers Squibb and Johnson & Johnson have a lot to offer investors.

2 No-Brainer Pharma Stocks to Buy Right Now

Evotec SE

8-YEAR EXTENSION AND EXPANSION OF COLLABORATION TO DEVELOP PIPELINE OF MOLECULAR GLUE DEGRADERS COLLABORATION LEVERAGES EVOTEC'S PROPRIETARY EVO PANOMICS AND EVO PANHUNTER PLATFORMS COVERING HIGH-PERFORMANCE MULTI-OMICS AND INTEGRATED AI/ML-SUPPORTED DATA ANALYTICS $ 200 M UPFRONT AS WELL AS NEAR-TERM PERFORMANCE-BASED PAYMENTS DEAL POTENTIAL OF $ 5 BN HAMBURG, GERMANY / ACCESSWIRE / May 10, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company has extended and expanded its partnership with Bristol Myers Squibb (NYSE:BMY) in targeted protein degradation, originally signed in 2018. The initial collaboration has proven to be highly productive in generating a promising pipeline of molecular glue degraders.

News for Bristol-Myers Stock (BMY)